Deferoxamine-induced electronegative ERG responses

Springer Science and Business Media LLC - Tập 137 - Trang 15-23 - 2018
Ruben Jauregui1,2,3, Karen Sophia Park1,2, Alexander G. Bassuk4, Vinit B. Mahajan5,6, Stephen H. Tsang1,2,7,8
1Department of Ophthalmology, Columbia University, New York, USA
2Jonas Children’s Vision Care and Bernard & Shirlee Brown Glaucoma Laboratory, New York, USA
3Weill Cornell Medical College, New York, USA
4Department of Pediatrics, University of Iowa, Iowa City, USA
5Byers Eye Institute, Omics Laboratory, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, USA
6Palo Alto Veterans Administration, Palo Alto, USA
7Department of Pathology and Cell Biology, Stem Cell Initiative (CSCI), Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, USA
8Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, USA

Tóm tắt

To report a case of deferoxamine-induced retinopathy characterized by electroretinography (ERG), optical coherence tomography angiography (OCT-A), and other multimodal imaging. This is an observational case report of one patient. Full-field ERG was performed. OCT-A, spectral-domain optical coherence tomography (SD-OCT), color fundus photography, and fundus autofluorescence were used to characterize the retinopathy induced by deferoxamine use. A 64-year-old man with a history of β-thalassemia intermedia presented with worsening visual acuity, nyctalopia, and electronegative ERG. OCT-A revealed atrophy of the choriocapillaris in areas of hypoautofluorescence, corresponding to regions of retinal atrophy. SD-OCT showed disruption of the ellipsoid zone, granular hyperreflective deposits within the retinal pigment epithelium, thinning of the retinal layers, and extensive choroidal sclerosis and atrophy of the retinal pigment epithelium. Deferoxamine-induced retinopathy can manifest with electronegative maximal ERG responses, and OCT-A can be used to detect deferoxamine toxicity.

Tài liệu tham khảo

Brittenham GM (2011) Iron-chelating therapy for transfusional iron overload. N Engl J Med 364:146–156 Bayanzay K, Alzoebie L (2016) Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: Current perspectives. J Blood Med 7:159–169 Gelman R, Kiss S, Tsang SH (2014) Multimodal imaging in a case of deferoxamine-induced maculopathy. Retin Cases Brief Rep 8:306–309 Di Nicola M, Barteselli G, Dell’Arti L, Ratiglia R, Viola F (2015) Functional and structural abnormalities in deferoxamine retinopathy: a review of the literature. Biomed Res Int 2015:249617 Viola F, Barteselli G, Dell’arti L, Vezzola D, Villani E, Mapelli C, Zanaboni L, Cappellini MD, Ratiglia R (2012) Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology 119:1693–1700 El-Shazly AA, Ebeid WM, Elkitkat RS, Deghedy MR (2017) Electroretinographic and visual-evoked potential changes in relation to chelation modality in children with thalassemia. Retina 37:1168–1175 Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S (2002) Deferoxamine retinopathy study G: the expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109:164–171 Wu CH, Yang CP, Lai CC, Wu WC, Chen YH (2014) Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol 14:88 Zeitz C, Robson AG, Audo I (2015) Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res 45:58–110 Audo I, Robson AG, Holder GE, Moore AT (2008) The negative erg: clinical phenotypes and disease mechanisms of inner retinal dysfunction. Surv Ophthalmol 53:16–40 Raghuram A, Hansen RM, Moskowitz A, Fulton AB (2013) Photoreceptor and postreceptor responses in congenital stationary night blindness. Invest Ophthalmol Vis Sci 54:4648–4658 Tsui I, Casper D, Chou CL, Tsang SH (2008) Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy. Doc Ophthalmol 116:57–60 Spaide RF, Klancnik JM Jr, Cooney MJ (2015) Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 133:45–50 Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG, Georgalas I (2016) Beta-thalassemia and ocular implications: a systematic review. BMC Ophthalmol 16:102 Reddy S, Iturralde D, Meyerle C, Gross NE, Yannuzzi LA (2007) Fundus autofluorescence in retinopathy caused by deferoxamine toxicity. Retin Cases Brief Rep 1:120–122 Munk MR, Giannakaki-Zimmermann H, Berger L, Huf W, Ebneter A, Wolf S, Zinkernagel MS (2017) Oct-angiography: a qualitative and quantitative comparison of 4 oct-a devices. PLoS ONE 12:e0177059 Merchant RH, Punde H, Thacker N, Bhatt D (2017) Ophthalmic evaluation in beta-thalassemia. Indian J Pediatr 84:509–514 Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV (2010) Serum ferritin: past, present and future. Biochim Biophys Acta 1800:760–769 Klettner A, Koinzer S, Waetzig V, Herdegen T, Roider J (2010) Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. Cutan Ocul Toxicol 29:122–129 Kurihara T, Westenskow PD, Gantner ML, Usui Y, Schultz A, Bravo S, Aguilar E, Wittgrove C, Friedlander M, Paris LP, Chew E, Siuzdak G, Friedlander M (2016) Hypoxia-induced metabolic stress in retinal pigment epithelial cells is sufficient to induce photoreceptor degeneration. Elife 5:e14319. https://doi.org/10.7554/eLife.14319